Interference of IP-10 Expression Inhibits Vascular Smooth Muscle Cell Proliferation and Intimal Hyperplasia in Carotid Artery: A New Insight in the Prevention of Restenosis

Cell Biochemistry and Biophysics

Volumn 62, Issue 1, 2012, Pages 125-135

  Zuojun, Hu ^a   Lingyu, Hu ^a   Wei, He ^a   Henghui, Yin ^a   Chonggang, Zhang ^a   Jingsong, Wang ^a   Mian, Wang ^a   Yong, Liu ^a   Shenming, Wang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Intimal hyperplasia; IP 10; Restenosis; siRNA; Smooth muscle cells

Indexed keywords

CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SMALL INTERFERING RNA;

AGED; ANIMAL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; COMMON CAROTID ARTERY; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; FEMALE; GENETICS; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RABBIT; RESTENOSIS; RNA INTERFERENCE; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CAROTID ARTERY, COMMON; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL10; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; RABBITS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUNICA INTIMA;

EID: 84855591684     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9270-9     Document Type: Article

References (36)

1. Yajima, N., Takahashi, M., Morimoto, H., et al. (2008). Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation, 117, 3079-3087.
2. Luster, A. D., Unkeless, J. C., & Ravetch, J. V. (1985). Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature, 315, 672-676.
3. Taub, D. D., Lloyd, A. R., Conlon, K., et al. (1993). Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. The Journal of Experimental Medicine, 177, 1809-1814.
4. Glass, W. G., Subbarao, K., Murphy, B., & Murphy, P. M. (2004). Mechanisms of host defense following severe acute respiratory syndrome-coronavirus [SARS-CoV] pulmonary infection of mice. The Journal of Immunology, 173, 4030-4039.
5. Tang, N. L., Chan, P. K., Wong, C. K., et al. (2005). Early enhanced expression of interferon inducible protein-10 [CXCL-10] and other chemokines predict adverse outcome in severe acute respiratory syndrome. Clinical Chemistry, 51, 2333-2340.
6. Deng, G., Zhou, G., Zhang, R., et al. (2008). Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology, 134, 716-726.
7. Ruhwald, M., Bjerregaard-Andersen, M., Rabna, P., Kofoed, K., Eugen-Olsen, J., & Ravn, P. (2007). CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7. 7. Microbes and Infection, 9, 806-812.
8. Hanifi-Moghaddam, P., Schloot, N. C., Kappler, S., Seissler, J., & Kolb, H. (2003). An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes, 52, 1137-1142.
9. Shimada, A., Morimoto, J., Kodama, K., et al. (2001). Elevated serum IP-10 levels observed in type-1 diabetes. Diabetes Care, 24, 510-515.
10. Nicoletti, F., Conget, I., Di Mauro, M., et al. (2002). Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia, 45, 1107-1110.
11. Romagnani, P., Rotondi, M., Lazzeri, E., et al. (2002). Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. American Journal of Pathology, 161, 195-206.
12. Mariotti, S., del Prete, G. F., Mastromauro, C., et al. (1991). The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis. Clinical Endocrinology, 97, 139-146.
13. Garcia-Lopez, M. A., Sancho, D., Sanchez-Madrid, F., & Marazuela, M. (2001). Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3 + lymphocytes. Journal of Clinical Endocrinology and Metabolism, 86, 5008-5016.
14. Lasagni, L., Francalanci, M., Annunziato, F., et al. (2003). An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. The Journal of Experimental Medicine, 197, 1537-1549.
15. Lazzeri, E., & Romagnani, P. (2005). CXCR3-binding chemokines: novel multifunctional therapeutic targets. Current Drug Targets: Immune, Endocrine & Metabolic Disorders, 5, 109-118.
16. Melter, M., Exeni, A., Reinders, M. E., et al. (2001). Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation, 104, 2558-2564.
17. Zhao, D. X., Hu, Y. Y., Miller, G. G., Luster, A. D., Mitchell, R. N., & Libby, P. (2002). Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. The Journal of Immunology, 169, 1556-1560.
18. Fahmy, N. M., Yamani, M. H., Starling, R. C., et al. (2003). Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation, 75, 72-78.
19. Kao, J., Kobashigawa, J., Fishbein, M. C., et al. (2003). Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation, 107, 1958-1961.
20. Wang, X., Yue, T. L., Ohlstein, E. H., Sung, C. P., & Feuerstein, G. Z. (1996). Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. The Journal of Biological Chemistry, 271, 24286-24293.
21. Mach, F., Sauty, A., & Iarossi, A. S. (1999). Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. The Journal of Clinical Investigation, 104, 1041-1050.
22. Han, D. K., Haudenschild, C. C., Hong, M. K., Tinkle, B. T., Leon, M. B., & Liau, G. (1995). Evidence for apoptosis is in human atherogenesis and in a rat vascular injury model. American Journal of Pathology, 147, 267-278.
23. Luisis, A. J. (2000). Atherosclerosis. Nature, 407, 233-241.
24. Sedding, D. G., Tröbs, M., Reich, F., et al. (2009). 3-Deazaadenosine prevents smooth muscle cell proliferation and neointima formation by interfering with Ras signaling. Circulation Research, 104, 1192-1200.
25. Dzau, V. J., Braun-Dullaeus, R. C., & Sedding, D. G. (2002). Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nature Medicine, 8, 1249-1256.
26. Hodges-Garcia, Y. K., Madigan, N., & Horwitz, L. D. (1998). Primary human vascular smooth muscle cell culture enhanced by human umbilical cord serum. In Vitro Cellular & Developmental Biology Animal, 34, 364-366.
27. Schwartz, M. A. K., Lieske, J. C., Kumar, V., Farell-Baril, G., & Miller, V. M. (2008). Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: Proof of principle. International Journal of Nanomedicine, 3, 243-248.
28. Rotmans, J. I., Velema, E., Verhagen, H. J., et al. (2004). Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. Journal of Vascular Surgery, 39, 432-439.
29. Mazzone, A., De Servi, S., Ricevuti, G., et al. (1993). Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation, 88, 358-363.
30. Khorsandi, M. J., Fagin, J. A., Giannella-Neto, D., Forrester, J. S., & Cercek, B. (1992). Regulation of insulin-like growth factor I and its receptor in rat aorta after balloon denudation: evidence for local bioactivity. The Journal of Clinical Investigation, 90, 1926-1931.
31. Linder, V., & Reidy, M. A. (1993). Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. Circulation Research, 73, 589-595.
32. Bornfeldt, K. E., Raines, E. W., Nakano, T., Graves, L. M., Krebs, E. G., & Ross, R. (1994). Insulin-like growth factor-I and platelet-derived growth factor-B induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. The Journal of Clinical Investigation, 93, 1266-1274.
33. McCaffrey, T. A. (2000). TGF-beta and TGF-beta receptor in atherosclerosis. Cytokine Growth Factor Review, 11, 103-114.
34. Bayes, G. A., Conover, C. A., & Schwartz, R. S. (2000). The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circulation Research, 86, 125-130.
35. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998). Potent and specific genetic interference by double 2 strand RNA in Caenorhabditis elegans. Nature, 391, 744-745.
36. Kusaba, K., Kai, H., & Koga, M. (2007). Inhibition of intrinsic Interferon-γ function prevents neointima formation after balloon injury. Hypertension, 49, 909-915.